CN1416728A - 一种增加骨密度和延缓衰老的保健食品及其制备方法 - Google Patents
一种增加骨密度和延缓衰老的保健食品及其制备方法 Download PDFInfo
- Publication number
- CN1416728A CN1416728A CN02151147A CN02151147A CN1416728A CN 1416728 A CN1416728 A CN 1416728A CN 02151147 A CN02151147 A CN 02151147A CN 02151147 A CN02151147 A CN 02151147A CN 1416728 A CN1416728 A CN 1416728A
- Authority
- CN
- China
- Prior art keywords
- extraction
- health food
- bone density
- angelicae sinensis
- radix angelicae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000037182 bone density Effects 0.000 title claims abstract description 33
- 235000013402 health food Nutrition 0.000 title claims abstract description 23
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 230000001965 increasing effect Effects 0.000 title abstract description 4
- 239000000843 powder Substances 0.000 claims abstract description 22
- 238000000605 extraction Methods 0.000 claims abstract description 18
- 244000068988 Glycine max Species 0.000 claims abstract description 14
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 14
- 229920002472 Starch Polymers 0.000 claims abstract description 11
- 229960004494 calcium gluconate Drugs 0.000 claims abstract description 11
- 239000004227 calcium gluconate Substances 0.000 claims abstract description 11
- 235000013927 calcium gluconate Nutrition 0.000 claims abstract description 11
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims abstract description 11
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000008696 isoflavones Nutrition 0.000 claims abstract description 11
- 235000019698 starch Nutrition 0.000 claims abstract description 11
- 239000008107 starch Substances 0.000 claims abstract description 11
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 10
- 239000011734 sodium Substances 0.000 claims abstract description 10
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 10
- 244000061520 Angelica archangelica Species 0.000 claims abstract description 7
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 7
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims abstract description 7
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims abstract description 7
- 238000001694 spray drying Methods 0.000 claims abstract description 6
- 238000002481 ethanol extraction Methods 0.000 claims abstract description 4
- 238000003809 water extraction Methods 0.000 claims abstract description 4
- 239000000047 product Substances 0.000 claims description 24
- 210000000582 semen Anatomy 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 238000005303 weighing Methods 0.000 claims description 13
- 239000009636 Huang Qi Substances 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 8
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 8
- 230000003712 anti-aging effect Effects 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 6
- 241001061264 Astragalus Species 0.000 claims description 5
- 235000006533 astragalus Nutrition 0.000 claims description 5
- 239000007888 film coating Substances 0.000 claims description 5
- 238000009501 film coating Methods 0.000 claims description 5
- 210000004233 talus Anatomy 0.000 claims description 5
- 229920001661 Chitosan Polymers 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000007670 refining Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 abstract description 10
- 239000011248 coating agent Substances 0.000 abstract description 2
- 238000000576 coating method Methods 0.000 abstract description 2
- 241000893536 Epimedium Species 0.000 abstract 2
- 240000000249 Morus alba Species 0.000 abstract 2
- 235000008708 Morus alba Nutrition 0.000 abstract 2
- 229940107666 astragalus root Drugs 0.000 abstract 2
- 235000018905 epimedium Nutrition 0.000 abstract 2
- 238000002156 mixing Methods 0.000 abstract 1
- 238000005453 pelletization Methods 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 28
- 239000000523 sample Substances 0.000 description 28
- 230000000694 effects Effects 0.000 description 25
- 210000000689 upper leg Anatomy 0.000 description 21
- 210000000988 bone and bone Anatomy 0.000 description 16
- 210000003734 kidney Anatomy 0.000 description 15
- 230000037396 body weight Effects 0.000 description 14
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 11
- 241000282414 Homo sapiens Species 0.000 description 11
- 229960005069 calcium Drugs 0.000 description 11
- 239000011575 calcium Substances 0.000 description 11
- 229910052791 calcium Inorganic materials 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 239000000306 component Substances 0.000 description 9
- 102000019197 Superoxide Dismutase Human genes 0.000 description 8
- 108010012715 Superoxide dismutase Proteins 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 238000005189 flocculation Methods 0.000 description 7
- 230000016615 flocculation Effects 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 239000013049 sediment Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000032683 aging Effects 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 6
- -1 lipid peroxide Chemical class 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 208000001132 Osteoporosis Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 235000013399 edible fruits Nutrition 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 4
- 235000019219 chocolate Nutrition 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 229940011871 estrogen Drugs 0.000 description 4
- 230000001076 estrogenic effect Effects 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 3
- 231100000111 LD50 Toxicity 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 235000003969 glutathione Nutrition 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- 210000002997 osteoclast Anatomy 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000000528 statistical test Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 208000008035 Back Pain Diseases 0.000 description 2
- 241000288673 Chiroptera Species 0.000 description 2
- 241000255601 Drosophila melanogaster Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- MRELNEQAGSRDBK-UHFFFAOYSA-N lanthanum(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[La+3].[La+3] MRELNEQAGSRDBK-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 238000004137 mechanical activation Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011812 mixed powder Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 231100000628 reference dose Toxicity 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241000045500 Diseae Species 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 229930187719 Soyasaponin Natural products 0.000 description 1
- 206010041611 Spine malformation Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960004343 alendronic acid Drugs 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000012805 animal sample Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000008394 flocculating agent Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 102000036124 hormone binding proteins Human genes 0.000 description 1
- 108091011044 hormone binding proteins Proteins 0.000 description 1
- 230000003483 hypokinetic effect Effects 0.000 description 1
- TZJALUIVHRYQQB-XLRXWWTNSA-N icariin Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-XLRXWWTNSA-N 0.000 description 1
- TZJALUIVHRYQQB-UHFFFAOYSA-N icariine Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229930013032 isoflavonoid Natural products 0.000 description 1
- 150000003817 isoflavonoid derivatives Chemical class 0.000 description 1
- 235000012891 isoflavonoids Nutrition 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000006101 laboratory sample Substances 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000009645 skeletal growth Effects 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/05—Mashed or comminuted pulses or legumes; Products made therefrom
- A23L11/07—Soya beans, e.g. oil-extracted soya bean flakes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Agronomy & Crop Science (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
一种增加骨密度和延缓衰老的保健食品,它是以大豆,淫羊藿,黄芪,当归和桑椹为有效成分,再配之以辅料葡萄糖酸钙,羧甲基淀粉钠和微晶纤维素组成。该保健食品的制备方法是将通过超临界CO2提取工艺制得的当归油,大豆通过乙醇提取制得的大豆异黄酮提取物,和由淫羊藿、黄芪,桑椹及提油后的当归粉通过水提取及处理后制得的喷干粉充分混合,再加入葡萄糖酸钙,羧甲基淀粉钠和微晶纤维素,制得颗粒,再压片,包衣,即得成品片剂。动物实验证明该产品具有增加骨密度和延缓衰老的作用。现代药理和临床研究表明,本发明产品具有增加骨密度和延缓衰老的保健功能,适宜作为保健食品长期服用。
Description
技术领域
本发明涉及一种增加骨密度和延缓衰老的保健食品,是关于一种以药食两用原料为主制成的增加骨密度和延缓衰老的保健食品及其制备方法。
背景技术
衰老是随着年龄的增加而出现的机体组织结构变化和功能减退的一种自然发展过程。伴随着人体衰老,机体骨代谢也会出现紊乱,成骨细胞和破骨细胞作用间的平衡被打破,骨吸收大于骨形成,引起骨量减少,骨密度下降,最终导致骨质疏松,可有腰背疼痛、脊椎畸形,并且极易骨折,严重影响了人们的生活质量。骨密度下降和骨质疏松在绝经后的老年妇女中尤为严重,患病率高达50%左右。目前市场上尚未有很好的治疗方法。有人运用***替代疗法来预防和治疗骨密度的下降,防止骨质疏松的发生。但是,多项研究表明,运用***替代疗法可明显增加子宫内膜癌和乳腺癌的发生率,因而并非是一种十分理想的治疗方法。因此开发增加骨密度和延缓衰老的保健食品十分必要。
发明内容
本发明是提供一种增加骨密度和延缓衰老的保健食品及其制备方法。
本发明产品是根据传统中医药理论和保健养生理论开发的保健食品,是以大豆,淫羊藿,黄芪,当归,桑椹为有效成分,再配之以辅料葡萄糖酸钙,羧甲基淀粉钠和微晶纤维素组成。
本发明保健食品的组分及其重量份含量如下:
组分 | 大豆 淫羊藿 黄芪 当归 桑椹 葡萄糖酸钙 羧甲基淀粉钠 微晶纤维素 |
重量份 | 1040 3-10 3-10 3-10 1-10 0.3-3 0.1-3 0.1-3 |
本发明保健食品组分的最佳含量为
组分 | 大豆 淫羊藿 黄芪 当归 桑椹 葡萄糖酸钙 羧甲基淀粉钠 微品纤维素 |
重量份 | 20 10 10 5 5 0.4 0.3 0.3 |
配方中的大豆、淫羊藿、黄芪、当归和桑椹经现代药理和临床研究表明,具有一定的增加骨密度和延缓衰老的功能,适宜作为保健食品长期服用。以下按照保健功能分类分别阐述其配方依据。
增加骨密度作用的配方依据:1)豆科植物大豆的提取物中含有丰富的异黄酮类化合物,对增加骨密度,改善骨质疏松有良好作用(Picherit C et al.J Nutri,2000,130(7):1675~1681)。大豆异黄酮是典型的植物***,并且具有双向调节作用,即体内***水平低下时,可以通过增加***受体的数目和亲和力,增加***的生物学效应,呈现***样作用;体内***水平高时,又可以调节体内的性激素结合蛋白,减弱***的生物学效应,表现出抗***样作用。因此,大豆异黄酮可以很好地调节机体内***水平的紊乱,并且没有激素类药物所不可避免的副作用。
2)现代药理实验研究表明,淫羊藿提取液存在着“补骨”作用,能抑制破骨细胞的活性,同时又能促进成骨细胞的功能,使钙化骨形成增加,增加骨密度,对骨质疏松有良好的防治效果(高素强等,中国中药杂志,1999,24(4):249~251)。
3)黄芪可使小鼠动情期明显延长,提示可能有促进***样作用;黄芪多糖可直接或间接作用于成骨细胞,抗骨质疏松(王拥军等,中国中医骨伤科杂志,1999,7(6):1~4)。
综上所述,本配方应具有增加骨密度的保健功能。
延缓衰老作用的配方依据:
1)大豆提取物中的大豆皂甙通过调节代谢,增加超氧化物岐化酶(SOD)的含量,降低过氧化脂质(LPO)浓度,从而降低或消除自由基对细胞的损伤,具有抗脂质氧化和降低氧化脂质的作用(郑高利等,浙江医科大学学报,1997,36(5):196~199)。
2)淫羊藿有延缓衰老的作用,可明显提高老龄动物血液及组织中SOD、谷胱甘肽过氧化物酶(GSH-PX)的活性,降低小鼠心肌脂褐质含量(曾南等,中国中药杂志,1997,22(1):46~48)。
3)黄芪含有多糖、单糖、黄酮类化合物、生物碱、叶酸、多种氨基酸、维生素、苦味素,以及硒、锌、铁等十四种人体所需要的微量元素。可降低年老大鼠主动脉和肺的胶原含量,延长细胞在体外生长的寿命;还可以使全血中超氧化物歧化酶活性明显增高,过氧化脂质含量明显减少,对氧自由基有很强的消除作用(雷红,中草药,1992,23(9):469~473)。
4)当归中的有效成分可以通过消除自由基、抑制氧化反应和自由基反应,以及与生物膜磷脂结合保护膜脂质等多种机理拮抗自由基对组织的损害。
5)桑椹中含有多种维生素和矿物质,具有很好的保健作用。现代药理研究还发现,桑椹可促进T淋巴细胞成熟,使衰老的T淋巴细胞功能得到恢复。
综上所述,本配方应具有延缓衰老的保健功能。
祖国医学认为,衰老的发展与肾脏的变化有着密切的关系,并且骨骼的生长、壮健和再生与肾的精气充盛是密不可分的。肾藏精,精生髓,髓生骨,故“骨者肾之合”也。《医经精义》:“肾的精气匮乏则发生骨病”。肾精肾气充实,则骨髓生化有源,骨骼坚固,强健有力;若肾气不足,肾精亏虚,则骨髓乏源,骨骼失养。可见,肾脏的变化是人体衰老的重要原因之一,直接影响着机体骨骼的坚固与否。因此,及早调理肾脏先天之本,将对强健骨骼,延缓衰老有着重要作用,调理重点当是补肾填精、益气养血,通过调整人体阴阳平衡,补髓壮骨,强骨延衰。
本发明产品根据中医辨证施治理论,本着未病先防和标本兼顾基本指导原则组方,方中大豆,性味甘平,入脾肾经。《本草汇篡》:“泽肌补骨”;淫羊藿,辛,甘,温,归肝肾经。《本草纲目》中称其有“坚筋骨,补腰膝,强心力”之功效,二者共用并为君药,温补肾中之阳气,充骨添髓。更用黄芪和当归配伍,益脾胃后天之本,气旺血生,气血充盈。桑椹,性味甘寒,功能滋阴养血,更防过热之虞。五味配伍,共达温补肾精,滋阴养血之效。
本发明配方组分考虑是以保健强身为目的,因此剂量不宜过大,参考治疗老年病及抗衰老健身的剂量,采用低于药物常用治疗剂量,参见表1。本发明组分中淫羊藿和黄芪均取常用治疗剂量的最低量,以保证其功效的发挥。
表1
治疗老年病参考剂量 | 抗衰老健身参考剂量 | 本发明最佳剂量 | |
大豆 | 5~30g/日 | 20g/日 | |
淫羊藿 | 10~12g/日 | 10g/日 | |
黄芪 | 10~15g/日 | 3~10g/日 | 10g/日 |
当归 | 10~15g/日 | 3~6g/日 | 5g/日 |
桑椹 | 10~15g/日 | 5g/日 |
配方中的葡萄糖酸钙,羧甲基淀粉钠和微晶纤维素为压片制剂所需的辅料,均符合国家标准。
将上述各组分制成本发明保健食品的制备方法,包括以下各步骤:
1、称取当归,粉碎后过筛20目,得到的当归粉末采用超临界CO2提取工艺进行提取:将粉末放入超临界CO2提取罐,提取压力为5-20MPa,提取温度为20-60℃;然后在分离罐中分离得当归油,备用,分离压力为1-1.5MPa,分离温度为15-20℃;液态CO2流量为20-40Nm3/h,在流程中循环使用进行提取,提取时间为1-3小时,从提取罐中取出提油后的当归粉,备用;
2、称取大豆,粉碎后过筛20目,得到的大豆粉末脱脂后用80%乙醇提取,提取液于60-80℃浓缩,再通过90-95%乙醇精制,干燥,得纯度为40%的大豆异黄酮提取物,备用;
3、称取淫羊藿,黄芪和桑椹,与上述备用的提油后的当归粉,用10-12倍(重量比)的水进行提取,加热至95-98℃亚沸状态,动态循环水提取1-3小时,提取液用60目滤网过滤,滤液在50-80℃及真空度0.04-0.09MPa下真空浓缩,至相对密度达1.03-1.04(60-65℃),再加入浓度为200-500ppm的壳聚糖,絮凝沉淀0.5-1小时,将絮凝沉淀液用200目微孔精密过滤,精滤液在50-80℃及真空度0.04-0.09MPa下真空浓缩,至浓缩液相对密度达1.08-1.10(60-65℃)。将所得浓缩液,喷雾干燥,得喷干粉;
4、将喷干粉与上述提取得的当归油和大豆异黄酮提取物充分混合,得混合干粉,再加入葡萄糖酸钙,羧甲基淀粉钠和微晶纤维素,搅拌混和,过筛80目,制粒,干燥,得颗粒;
5、将颗粒压片,薄膜包衣,即得成品片剂。
本发明的产品质量控制采用先进的高效液相色谱技术,对其功效成分进行监控定量分析,如异黄酮(以染料木黄酮计)≥2300mg/100g成品,淫羊藿甙≥300mg/100g成品,多糖(以葡聚糖计)≥160mg/100g成品,黄芪甲甙和阿魏酸均定性检出,从而确保产品质量的可靠性和稳定性。
本发明保健食品的外观是薄膜包衣片剂,内容物是棕褐色粉末,有本品药物组分的特殊气味,其口味微甘微苦。
对本发明保健食品取样进行急性毒性试验,样品对雌雄小白鼠的急性经口服LD50均大于10000mg/kg,以急性毒性半数致死量毒性分级,属无毒级物质。
本发明保健食品样品为粉红色或无色薄膜包衣片,人体推荐剂量为每日3.6g/60kg体重。经国家指定检验机构的功能评价实验表明:(1)经口给予动物样品3个月后,即具有增加大鼠骨密度的作用,样品能增加股骨重量、股骨干骺端骨密度、股骨中点骨密度及钙含量。(2)果蝇实验表明,本样品的各浓度组雌蝇可延长平均寿命3.60-4.93天;生化指标检测表明,本品具有降低血清过氧化脂质降解产物含量,升高血清谷胱甘肽过氧化物酶活力的作用。以上两个实验证明本发明产品具有增加骨密度和延缓衰老的作用。
经稳定性实验表明,本产品的有效期为至少两个月。样品置于温度为37-40℃,相对湿度为75%的条件下,每月检测一次,连续检测3个月。实验结果表明每次检验结果均符合GB16740-1997要求。如菌落总数<10cfu/g,大肠菌群<30MPN/100g,霉菌<10cfu/g,酵母<10cfu/g,致病菌(沙门氏菌、志贺氏菌、金黄色葡萄球菌和溶血性链球菌)未检出。铅<0.2mg/kg,砷<0.1mg/kg,汞未检出。
本产品以大豆、淫羊藿、黄芪、当归和桑椹作为主要原料,其中大豆、淫羊藿和黄芪不仅具有抑制破骨细胞的活性,促进成骨细胞,从而增加骨密度的功能,而且可以消除体内自由基,抗脂质氧化,具有延缓衰老的功能,再与滋阴补血,内含多种维生素和矿物质的当归和桑椹同用,共同达到增加骨密度和延缓衰老的功用,并且不会产生激素类药物的不良副作用。本产品的配方特点在于针对人体阴阳失衡的基本病因,从肾之本入手,调节整体平衡,重点在于促进体内钙的吸收,补髓壮骨,延年益寿。这与市场上一些单纯补钙的产品相比有很大不同,避免了一味补钙而不能吸收的缺点,另外本产品采用了全水薄膜包衣,遮盖了酒精异味的产生,适宜保健调养食品长期服用,是一种新型的纯天然保健食品。
还有,本发明的制备方法综合了多项先进工艺新技术,如亚沸动态提取、絮凝沉淀、微孔精密过滤、喷雾干燥、薄膜包衣制剂等,与传统制备方法相比,体现出先进、创新、科技含量高的特点。采用亚沸动态提取技术,与传统的静态提取相比,不仅使提取技术得到进一步提高,而且在节能、环保、劳动强度及提取时间和效率等方面都有明显的改善。絮凝沉淀采用良好的絮凝剂壳聚糖,它溶解在水提液中以电中和与吸附方式沉降带负电的粒子如杂质而未及多糖成份,经过滤即可达到精制的目的。而传统的乙醇沉淀工艺耗时长、回收繁琐以及对环境的特殊要求,越来越不适应现代工艺生产的要求。絮凝沉淀同时也可很好的保留产品中的多糖类活性成分、挥发性成分及多种微量元素,使产品的质量得到更好的保证。采用的微孔过滤技术,其中采用的微孔管符合卫生要求,孔径可根据要过滤的粒子大小而选择,可反复冲洗使用,设备占地面积小,喷雾干燥技术,使物料在瞬间得到干燥,减少了多糖类活性成分、挥发性成分的损失,使产品的质量提高。薄膜包衣制剂中薄膜包衣的包衣为水溶性,具有抗湿、避光、遮味、片型好等优点;使产品片剂不易碎裂,可以长时间保存,而且不含乙醇,更加安全,也符合环保的要求。本产品采用了多种先进技术,使整个工艺符合现代生产的需求,省时、省力、避免污染,形成了一条现代化的生产流水线。
具体实施方式
实施例1 本发明保健食品增加骨密度作用的实验
样品性状及处理:样品为粉红色包衣片,片芯是棕褐色粉末,人体推荐量为每日3.6g/60kg体重,实验设低、中、高三个剂量组:各组分别为0.30g、0.60g、1.80g/kg,相当于人体推荐剂量的5倍、10倍、30倍。同时设立三个对照组:假手术组、模型对照组、阳性对照组。
实验动物:Wistar大鼠,雌性,体重220-250克。
剂量设计:样品设低、中、高三个剂量组,分别将样品0.30g、0.60g、1.80g加入10ml去离子水,每日按10ml/kg.bw灌胃。
实验方法
1、卵巢切除:大鼠以30mg/kg.bw腹腔注射1%戊巴比妥钠溶液,麻醉后进行双侧卵巢切除,术后肌肉注射2万单位的青霉素,连续3天,假手术组打开腹腔后仅切除0.5左右的脂肪,保留双侧卵巢。
2、雌性Wistar大鼠按体重随机分为假手术组、模型对照组、阳性对照组及样品低、中、高三个剂量组,每组10只,单笼饲养,假手术组及模型对照组以去离子水灌胃,阳性对照组经口给予1.0mg/kg.bw的阿仑膦酸钠。整个实验期间大鼠饮用去离子水,每周纪录饲料摄入量,体重,身长;动物喂养至12周,颈椎脱臼处死大鼠,应用QDR-4000型骨密度仪测量大鼠股骨中点及股骨干骺端骨密度,然后解剖大鼠,剥离左侧股骨,用游标卡尺测量股骨的长度,将股骨烤干至恒重,称量骨干重。
3、骨钙测定:依据国家标准GB12398-90进行测定。称取样品于小三角烧瓶中,加5ml HNO3∶HCLO4(4∶1),上加漏斗,置于电热板上加热消化,如消化不完全,补加硝酸继续加热消化至无色透明为止,加2ml去离子水,加热以除去多余的硝酸。取下冷却,用2%氧化镧溶液定容至100ml容量瓶中。按上述操作做试剂空白。
C:仪器上得出的钙浓度(μg/ml)
W:样品称重(g)
V:样品定容体积(ml)
实验结果:
1、样品对大鼠体重的影响
表2样品对大鼠体重的影响
组别 | 动物数(只) | 体重(g) | ||||
始重 | 一月 | 二月 | 三月 | 增重(g/12周) | ||
假手术组模型对照组阳性对照组低剂量组中剂量组高剂量组 | 101010101010 | 232.4±6.9231.0±14.7233.2±6.9230.6±9.5235.7±8.5229.9±5.8 | 266.7±21.6293.0±20.2304.2±17.5287.9±23.1281.9±19.6276.1±21.6 | 283.1±34.4316.2±23.2329.3±27.9308.7±19.0307.9±19.0301.7±19.3 | 323.3±23.0369.2±23.5373.2±25.8356.5±18.7348.0±21.3335.8±15.1 | 90.9±25.2138.2±26.5140.0±26.7125.9±22.7112.3±26.4105.9±16.1 |
P<0.05(经方差分析)。
由表2可见,模型对照组1,2,3月体重明显高于假手术组(P<0.05),提示可能为动物在手术后***减少引起激素水平紊乱导致体重异常增长,说明模型成立。样品低、中剂量组及阳性对照组体重及体重增重与模型对照组相比无显著差异,样品高剂量组第3月体重及体重增重显著低于模型对照组。
2、样品对大鼠身长的影响
表3样品对大鼠身长的影响
组别 | 动物数(只) | 身长(cm) | ||||
初长 | 一月 | 二月 | 三月 | 增长(cm/12周) | ||
假手术组模型对照组阳性对照组低剂量组中剂量组高剂量组 | 101010101010 | 21.3±0.6421.4±0.8121.4±1.0621.4±0.9021.3±0.7621.5±0.35 | 22.3±0.7923.1±0.6822.4±0.7922.5±0.9022.7±0.8622.9±0.49 | 23.9±0.8924.7±0.7024.0±0.8424.1±0.9824.3±0.9024.5±0.48 | 24.3±0.9025.2±0.7224.4±0.8524.5±0.9924.8±0.9124.9±0.49 | 3.0±0.993.8±0.743.0±0.963.1±0.823.4±0.333.5±0.31 |
P<0.05(经方差分析)。由表3可见,各组大鼠各时期的身长及身长增长均无显著差异。
3、大鼠股骨的重量、长度、骨钙及股骨骨密度
表4样品对大鼠股骨的长度、重量、骨钙及骨密度的影响
P<0.05(经方差分析)。
组别 | 动物数(只) | 股骨长度(cm) | 股骨重量(g) | 股骨干骺端骨密度(g/cm2) | 股骨中点骨密度(g/cm2) | 骨钙含量(mg/g) |
假手术组模型对照组阳性对照组低剂量组中剂量组高剂量组 | 101010101010 | 3.44±0.343.46±0.343.45±0.273.47±0.293.52±0.403.49±0.35 | 0.68±0.0710.59±0.0520.67±0.0580.65±0.0600.68±0.0570.69±0.064 | 0.240±0.0260.195±0.0290.234±0.0280.207±0.0160.228±0.0370.234±0.029 | 0.227±0.0070.189±0.0200.221±0.0290.207±0.0350.218±0.0270.224±0.021 | 270.3±38.1180.7±55.8237.8±40.9223.5±40.2254.6±35.5273.9±309 |
由表4可见,各组大鼠的股骨长度均无显著差异;假手术组大鼠股骨重量、股骨干骺端骨密度、股骨中点骨密度及骨钙含量显著高于模型对照组;样品高、中剂量组股骨重量、股骨干骺端骨密度、股骨中点骨密度及骨钙含量显著高于模型对照组。表明本实验样品具有增加大鼠骨密度作用。
实施例2 本发明保健食品延长衰老作用的实验
A、果蝇生存试验
样品:为粉红色包衣片,片芯是棕褐色粉末。
试验动物:Oregon K野生型黑腹果蝇(Drosophila melanogaster)
剂量分组:根据人体推荐剂量为(3.6克/人·日),设1个空白对照组和4个剂量组,各剂量组培养基含样品的浓度分别为:0.01%、0.04%、0.12%和0.36%。
试验方法:收集8小时内新羽化的果蝇成虫,***麻醉下区分雌雄随机分组、分别称重后进行试验。每组用果蝇400只,雌雄各半。对照组给予普通玉米粉培养基;试验组分别给予含0.01%、0.04%、0.12%和0.36%样品的培养基。实验条件:气温25±1℃,相对湿度45~75%。每四天更换新鲜培养基一次。每天观察记录果蝇生存数和死亡数,直到果蝇全部死亡为止。计算出半数死亡天数、平均寿命和平均最高寿命等三个指标。试验结果:
表5样品对果蝇生存试验统计表
性别 试物浓度 果绳数 平均体重 半数死亡时间 平均寿命 平均最高寿命a(%) (只) (mg/20只) (d) (d) (d) |
雌 0 200 16.9±0.3 54 54.64±12.64 77.75 ±4.010.01 200 17.2±0.2 58 58.24±13.41** 82.20±4.15**0.04 200 17.0±0.4 60 59.57±12.39** 80.55±3.35*0.12 200 17.1±0.5 60 59.17±12.47** 78.65±2.760.36 200 17.0±0.3 51 51.72±14.24 77.45±2.95 |
雄 0 200 11.7±0.2 53 51.54±13.09 72.05±3.300.01 200 11.7±0.2 52 50.93±14.04 72.45±3.190.04 200 11.6±0.2 54 52.24±13.28 73.75±3.890.12 200 11.6±0.2 51 50.37±12.86 71.30±3.510.36 200 11.6±0.2 37 39.40±10.14 56.75±0.44 |
a由寿命最长的20只果蝇计算得出。
*试验组与对照组相比寿命延长,统计学检验有显著性(P<0.05)。
**试验组与对照组相比寿命延长,统计学检验有非常显著意义(P<0.01)。
由表5可见,在本实验条件下,0.01%、0.04%和0.12%浓度组雌蝇与对照组比较见到延长平均寿命3.60~4.93天;0.01%和0.04%浓度组雌蝇与对照组比较见到延长平均最高寿命4.45和2.80天,统计学检验均有显著意义(P<0.05或P<0.01)。
B、进行延长衰老作用生化指标检测
样品:为粉红色包衣片,片芯是棕褐色粉末。
实验动物:SD雄性老龄大鼠(18月龄)32只,随机分为四组,每组8只。
剂量设计:人体推荐剂量为3.6g/60kg.bw,以0.15g/kg.bw(2.5倍)、0.30g/kg.bw(5倍)、0.60g/kg.bw(10倍)为低、中、高三个剂量组,另设老龄对照组。
实验方法:采用饮水法(样品用少量水研磨后,稀释至所需剂量),连续喂饲45d,对照组给予蒸馏水饮用。第46d取血测定血清中过氧化脂质降解产物丙二醛(MDA)含量、血清中超氧化物歧化酶(SOD)活力、谷胱甘肽过氧化物酶(GSH-Px)活力。
实验结果
表6各组大鼠始末体重(
x±s)
组别 | 动物数(只) | 剂量(g/kg.bw) | 初始体重(g) | 终末体重(g) |
老龄对照 | 8 | 0.00 | 607.5±63.71 | 668.8±93.77 |
低剂量 | 8 | 0.15 | 605.8±86.64 | 679.8±57.31 |
中剂量 | 8 | 0.30 | 618.3±89.64 | 672.3±105.60 |
高剂量 | 8 | 0.60 | 630.0±97.28 | 695.0±83.40 |
表7各组大鼠血清MDA含量、SOD、GSH-Px活力测定结果(
x±S)
组别 | 动物数(只) | MDA(nmol/ml) | SOD(NU/ml) | GSH-Px(U) |
老龄对照 | 8 | 4.78±0.24 | 410.00±32.02 | 178.95±2.29 |
低剂量 | 8 | 4.14±0.58* | 413.24±27.05 | 182.54±2.11* |
中剂量 | 8 | 4.06±0.53* | 434.52±21.54 | 179.64±1.87 |
高剂量 | 8 | 4.82±0.27 | 416.47±11.25 | 178.54±2.64 |
*与老龄对照组比较,p<0.05。
实验结论:由表7结果显示低、中剂量组血清过氧化脂质降解产物丙二醛(MDA)含量明显低于对照组(P<0.05)、低剂量组血清谷胱甘肽过氧化物酶(GSH-Px)活力明显高于对照组(P<0.05),表明该样品具有一定的降低脂质过氧化作用和具有升高GSH-Px作用。
实施例3本发明保健食品的制备
1、称取当归生药250克,进行机械粉碎后,过筛20目,得到的粉末采用超临界CO2提取工艺进行提取,将粉末放入超临界CO2提取罐,提取压力为10Mpa,提取温度为40℃,然后在分离罐中分离得当归油0.75克,备用,分离压力为1Mpa,分离温度为20℃,液态CO2流量为25Nm3/h,在流程中循环使用进行提取,提取时间为2小时,从提取罐中取出提油后的当归粉249克,备用;
2、称取大豆1kg,进行机械粉碎后,过筛20目,得到的大豆粉末用正己烷脱脂后,干燥,除去溶剂。用80%乙醇提取,提取液于60℃浓缩,再通过90-95%乙醇重結晶,干燥,得纯度为40%大豆异黄酮提取物,备用;
3、称取淫羊藿500克,黄芪500克和桑椹250克,和上述备用的提油后的当归粉249克,用10倍(重量比)的水进行提取,加热至95-98℃亚沸状态,动态循环水提取1小时,提取液用60目滤网过滤,滤液在65℃及真空度0.08MPa下浓缩至相对密度达1.03-1.04(60-65℃)。再加入浓度为200ppm的壳聚糖,絮凝沉淀半小时,将絮凝沉淀液用200目微孔精密过滤,精滤液在65℃及真空度0.08Mpa下浓缩至浓缩液相对密度达1.08-1.10(60-65℃),将所得浓缩液喷雾干燥,得喷干粉;
4、将所得喷干粉与上述分别提取得到的当归油及大豆异黄酮提取物充分混合,得混合干粉,再加入葡萄糖酸钙20克,羧甲基淀粉钠15克,微晶纤维素15克,搅拌混和,过筛80目,制粒,采用巴氏消毒法,制粒后的物料在烘箱内热风(60±5℃)连续干燥4小时,得颗粒180克;
5、将颗粒压片,粉红色薄膜包衣,即得成品片剂200片,每片含0.9g克剂量。
服法:每天服2次,每次2片(成人推荐剂量为3.6g/60kg·天)。
Claims (3)
1、一种增加骨密度和延缓衰老的保健食品,其特征在于其组分及含量如下:
组分
大豆 淫羊藿 黄芪 当归 桑椹 葡萄糖酸钙 羧甲基淀粉钠 微晶纤维素
重量份
10-40 3-10 3-10 3-10 1-10 0.3-3 0.1-3 0.1-3
2、如权利要求1所述的保健食品,其特征在于其中各组分的含量是
组分
大豆 淫羊藿 黄芪 当归 桑椹 葡萄糖酸钙 羧甲基淀粉钠 微晶纤维素
重量份
20 10 10 5 5 0.4 0.3 0.3
3、权利要求1所述增加骨密度和延缓衰老的保健食品的制造方法,其特征在于该方法包括下列步骤:
(1)称取当归,粉碎,过筛20目,采用超临界CO2提取工艺进行提取:提取罐压力为5-20MPa,温度为20-60℃;分离罐压力为1-1.5MPa,分离温度为15-20℃;液态CO2流量为20-40Nm3/h,提取时间为1-3小时,提取分离得当归油及提油后的当归粉;
(2)称取大豆,粉碎,过筛20目,脱脂,用乙醇提取,提取液于60-80℃浓缩,再通过90-95%乙醇精制,干燥,得大豆异黄酮提取物;
(3)称取淫羊藿,黄芪和桑椹,与所述提油后的当归粉,用10-12倍(重量比)的水进行提取,加热至95-98℃亚沸状态,动态循环水提取1-3小时,提取液用60目滤网过滤,滤液在50-80℃及真空度0.04-0.09MPa下真空浓缩,至相对密度达1.03-1.04(60-65℃),再用壳聚糖精制,200目微孔精密过滤,所得精滤液真空浓缩至浓缩液相对密度达1.08-1.10(60-65℃),将所得浓缩液喷雾干燥,得喷干粉;
(4)将喷干粉与所述当归油和大豆异黄酮提取物混合,再加入葡萄糖酸钙,羧甲基淀粉和微晶纤维素,混和,过筛80目,制粒,干燥,得颗粒;
(5)将颗粒压片,薄膜包衣,即得成品片剂。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021511470A CN1176602C (zh) | 2002-12-06 | 2002-12-06 | 一种增加骨密度和延缓衰老的保健食品及其制备方法 |
PCT/CN2003/001017 WO2004052120A1 (fr) | 2002-12-06 | 2003-11-28 | Aliment sain pouvant augmenter la densite osseuse et ralentir le vieillissement |
AU2003289630A AU2003289630A1 (en) | 2002-12-06 | 2003-11-28 | A healthy food for increasing bone density and anti-aging |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB021511470A CN1176602C (zh) | 2002-12-06 | 2002-12-06 | 一种增加骨密度和延缓衰老的保健食品及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1416728A true CN1416728A (zh) | 2003-05-14 |
CN1176602C CN1176602C (zh) | 2004-11-24 |
Family
ID=4751933
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB021511470A Expired - Lifetime CN1176602C (zh) | 2002-12-06 | 2002-12-06 | 一种增加骨密度和延缓衰老的保健食品及其制备方法 |
Country Status (3)
Country | Link |
---|---|
CN (1) | CN1176602C (zh) |
AU (1) | AU2003289630A1 (zh) |
WO (1) | WO2004052120A1 (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1293870C (zh) * | 2003-12-26 | 2007-01-10 | 吴英萍 | 一种治疗骨质疏松症的药物及其制备方法 |
CN100356869C (zh) * | 2005-12-27 | 2007-12-26 | 武汉哈福科技有限公司 | 一种抗衰老和美容的保健食品 |
CN100356914C (zh) * | 2005-11-25 | 2007-12-26 | 上海大学 | 大豆异黄酮片剂的制备方法 |
CN100367952C (zh) * | 2003-09-30 | 2008-02-13 | 戴向国 | 一种含有l-苏糖酸钙和大豆异黄酮的组合物 |
CN100441555C (zh) * | 2004-04-09 | 2008-12-10 | 汪云 | 含白藜芦醇和大豆异黄酮的组合物及其制备方法与应用 |
CN101139378B (zh) * | 2007-10-24 | 2010-12-15 | 中国农业大学 | 一种从黄芪中提取毛蕊异黄酮-7-O-β-D-葡萄糖苷的方法 |
CN102144677A (zh) * | 2011-04-06 | 2011-08-10 | 中国药文化研究会 | 一种当归保健油,其制备方法及应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1096204A (zh) * | 1993-06-12 | 1994-12-14 | 李延明 | 抗原发性骨质疏松症冲剂及其加工方法 |
CN1038813C (zh) * | 1993-07-02 | 1998-06-24 | 周勇 | 一种治疗骨质疏松症的中药 |
CN1256921A (zh) * | 1998-12-17 | 2000-06-21 | 西安医科大学第一临床医学院 | 一种防治老年性骨质疏松抗衰老药物 |
CN1141092C (zh) * | 2001-01-19 | 2004-03-10 | 郭兴华 | 一种防治骨质疏松、癌症和降血脂组合物及其应用 |
-
2002
- 2002-12-06 CN CNB021511470A patent/CN1176602C/zh not_active Expired - Lifetime
-
2003
- 2003-11-28 AU AU2003289630A patent/AU2003289630A1/en not_active Abandoned
- 2003-11-28 WO PCT/CN2003/001017 patent/WO2004052120A1/zh not_active Application Discontinuation
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100367952C (zh) * | 2003-09-30 | 2008-02-13 | 戴向国 | 一种含有l-苏糖酸钙和大豆异黄酮的组合物 |
CN1293870C (zh) * | 2003-12-26 | 2007-01-10 | 吴英萍 | 一种治疗骨质疏松症的药物及其制备方法 |
CN100441555C (zh) * | 2004-04-09 | 2008-12-10 | 汪云 | 含白藜芦醇和大豆异黄酮的组合物及其制备方法与应用 |
CN100356914C (zh) * | 2005-11-25 | 2007-12-26 | 上海大学 | 大豆异黄酮片剂的制备方法 |
CN100356869C (zh) * | 2005-12-27 | 2007-12-26 | 武汉哈福科技有限公司 | 一种抗衰老和美容的保健食品 |
CN101139378B (zh) * | 2007-10-24 | 2010-12-15 | 中国农业大学 | 一种从黄芪中提取毛蕊异黄酮-7-O-β-D-葡萄糖苷的方法 |
CN102144677A (zh) * | 2011-04-06 | 2011-08-10 | 中国药文化研究会 | 一种当归保健油,其制备方法及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN1176602C (zh) | 2004-11-24 |
WO2004052120A1 (fr) | 2004-06-24 |
AU2003289630A1 (en) | 2004-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108850366A (zh) | 一种具有降尿酸作用的代用茶组合物及其制备方法 | |
CN102406860A (zh) | 预防和治疗糖尿病的组合物、其制备方法及应用 | |
CN103251671A (zh) | 一种增加骨密度的含中药的组合物及其制备方法 | |
CN1457808A (zh) | 一种铁皮石斛复方制剂及制备和应用 | |
CN101966222A (zh) | 一种具有壮骨功效的药物组合物、制剂及其制备方法 | |
CN106072626B (zh) | 一种朝医复方鹿茸保健食品及其制备方法和用途 | |
CN1176602C (zh) | 一种增加骨密度和延缓衰老的保健食品及其制备方法 | |
CN1864530A (zh) | 一种高寒山区作物精制健康食品及其加工工艺 | |
CN101057916A (zh) | 一种降血脂的中药组合物及其制备方法 | |
CN1281161C (zh) | 一种具有抗疲劳作用的保健食品及其工艺方法 | |
CN1923256A (zh) | 一种药物组合物及其制备方法和质量控制方法 | |
CN104758556B (zh) | 一种抗动物热应激的复方制剂及其制备方法 | |
CN100345566C (zh) | 一种用于减肥的药物组合物及其制备方法和用途 | |
CN113499366B (zh) | 一种具有同时降低血糖血脂功能的组合物及其制备方法 | |
CN1231255C (zh) | 以南瓜为主要原料制备的治疗便秘的胶囊配方及配制方法 | |
CN100340266C (zh) | 一种降脂益肝的胶囊及其制备方法 | |
CN113209217A (zh) | 一种抗体力疲劳中药组合物及其制备方法 | |
CN1283269C (zh) | 复方蛤士蟆制剂及其制备方法 | |
CN108552525B (zh) | 一种降脂减肥功能食品 | |
CN1070827A (zh) | 糖尿病最新治疗剂及其制法 | |
CN108619483B (zh) | 一种可平衡膳食营养的降糖膳食蚕蛹提取生物蛋白 | |
CN1232274C (zh) | 一种防治骨质疏松的药物组合物及其应用 | |
CN1284482C (zh) | 一种调节免疫、降低血糖的营养食品及其制造方法 | |
CN1199683C (zh) | 一种降血脂和延缓衰老药物组合物及药物 | |
CN101785815A (zh) | 一种辅助降血脂、对化学性肝损伤有辅助保护功能的保健品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: SHANGHAI MODERN TCM CO., LTD. Free format text: FORMER NAME: SHANGHAI MODERN CHINESE TRADITIONAL MEDICINE TECHNOLOGY DEVELOPMENT CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: Shanghai city 200051 Days Road Lane 600 Civic Plaza East 7F-C Patentee after: Shanghai Sundise Chinese Medicine Technology Development Co.,Ltd. Address before: Shanghai city 200051 Days Road Lane 600 Civic Plaza East 7F-C Patentee before: Shanghai Sundise |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20041124 |